1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Valerio Therapeutics

Valerio Therapeutics

0.39
EUR
+0.00
(-0.51%)
11.54MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.07
0.54
0.09
0.09
0.19
0.11
0.06
0.02
0.05
0.01
0.01
0.01
0.01
- -
Basic EPS, GAAP
-0.74
-0.19
-0.48
-0.48
-1.16
-0.18
-0.47
0.01
-0.07
-0.18
-0.15
-0.16
-0.02
- -
Free Cash Flow per Basic Share
-0.68
-0.19
-0.58
-0.38
-0.56
-0.21
-0.11
-0.07
-0.1
-0.09
-0.13
-0.06
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.36
2.99
2.52
1.99
0.98
0.85
0.28
0.37
0.36
0.2
0.1
-0.06
- -
-0.06
Tangible Book Value per Share
0.36
0.83
0.4
0.15
0.05
0.13
-0.1
0.11
0.14
0.02
-0.04
-0.14
-0.01
-0.14
Basic Weighted Avg Shares
21
41
41
47
51
54
71
73
88
106
135
154
274
159
Sales/Revenue/Turnover
1
22
3
4
10
6
4
2
4
1
2
2
3
- -
Operating Margin (%)
-1,051.44
-2.8
-636.82
-523.67
-698.1
-255.31
-228.43
-439.98
-137.42
-1,185.93
-1,058.5
-919.58
-21.38
- -
Depreciation Expense
- -
1
2
2
40
9
25
-8
1
- -
2
11
5
- -
Net Income, GAAP
-15
-8
-19
-23
-59
-9
-34
1
-6
-20
-20
-24
-5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
40.99
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,044.83
-34.87
-557.41
-512.45
-621.47
-153.4
-786.57
61.32
-146.16
-1,355.65
-1,130.22
-1,334.02
-190.36
- -
Working Capital
10
50
31
24
11
12
5
17
23
13
2
-14
-2
-14
LT Debt
- -
- -
- -
- -
5
7
7
4
7
9
7
6
7
6
Total Equity
8
122
103
94
50
45
17
29
33
22
15
-8
2
-8
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-14.96
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
5.42
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-156.13
-11.86
-17.27
-23.03
-82.06
-19.73
-107.76
4.71
-19.16
-70.86
-109.75
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
2
2
8
LT Borrowings
7
11
6
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
154
154
154
Market Capitalization
25
16
12

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
13
9
5
Cash, Cash Equivalents & STI
7
4
1
Accounts Receivable, Net
2
- -
2
Inventories
- -
- -
- -
Total Current Liabilities
11
10
18
Payables & Accruals
- -
- -
- -
ST Debt
2
2
8
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.11%
-66.68%
-125.11%
Free Cash Flow
-7.94%
3.2%
-106%
Net Income, GAAP
-22.47%
-94.73%
-79.52%
Sales/Revenue/Turnover
14.99%
26.42%
43.5%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
2
2025
- -
- -
3

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.15
2024
- -
- -
-0.16
2025
- -
- -
-0.02

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gilles Besin
Full Time Employees
25
Sector
Health technology
Industry
Pharmaceuticals: major
Address
49, Bd du Général Martial Valin Paris IF France 75015
IPO Date
Nov 23, 2005
Website
valeriotx.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company that develops precision-guided therapeutics targeting complex and underserved diseases, including oncology and inflammatory disorders, through its proprietary V-Body platform of fully synthetic single-domain antibodies (sdAbs) and complementary chemistry capabilities; the V-Body platform, comprising human VH-derived and fully humanized VHH libraries (~15 kDa), enables deep tissue penetration, high specificity, and targeted delivery via drug conjugates, radio-conjugates, bispecific T-cell engagers, blocking sdAbs, and CAR-T sdAb drugs; additional offerings include the PlatON platform for DecoyTAC molecules combining cell-penetrating DNA decoys with linker-E3 ligands. The company focuses on advancing candidates from preclinical stages to proof-of-concept before strategic partnerships, co-development, or out-licensing, serving target markets in autoimmune diseases, inflammation, and solid tumors such as HRD+ ovarian cancer and HRRm/HRD+ tumors. Founded in 1997 and headquartered at 49 Boulevard du Général Martial Valin, Paris, France, Valerio Therapeutics operates primarily in Europe with prior U.S. presence now closed. In recent developments, Valerio Therapeutics acquired Emglev Therapeutics in September 2024 through its subsidiary Valour Bio to integrate proprietary sdAb technology, enhancing multimodal therapeutic development; the company discontinued all clinical trials, including the Phase 1/2 VIO-01 pan-DDR DNA decoy study in February 2025 amid financing challenges, shifting focus exclusively to early-stage research on its single-chain antibody platform combined with oligonucleotides and chemistry expertise; it closed its U.S. office in Lexington, MA, as part of this strategic refocus to ensure financial sustainability. Further restructuring includes a proposed simplified merger with Valour Bio (90.01%-owned), following Valour Bio's absorption of Emglev, to streamline the group structure effective retroactively from January 1, 2025, with approval pending Valour Bio shareholder vote in December 2025; additional actions encompass a capital increase with cancelled preferential rights in October 2025, share capital transactions to restructure liabilities in July 2025, and board composition changes in November 2025.